Related Experiment Videos
Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top"
Matteo Simonelli1, Pasquale Persico2, Matteo Perrino2
1Humanitas University, Department of Biomedical Sciences, Pieve Emanuele, MI, Italy; Humanitas Cancer Center, Humanitas Research Hospital, Rozzano, MI, Italy.
Abstract:
Glioblastoma is the most common and lethal malignant brain tumor in adults, with a very poor prognosis of less than two years despite surgical resection followed by radiotherapy and chemotherapy. To date, targeted agents and antiangiogenic therapy have failed to show survival benefits and novel treatment approaches are urgently needed. Immune checkpoint inhibitors have recently revolutionized the landscape of cancer immunotherapy achieving regulatory approvals for a number of other 'historically' resistant cancers. These exciting successes have generated great interest in investigating if these agents could be such effective also in brain tumors field. Moreover, the traditional dogma that considers the central nervous system (CNS) as an immune-privileged site lacking the potential for immunosurveillance has been challenged as it has become clear that the CNS is immunoactive. Critical barriers to an effective antitumor immunity in brain tumor patients are still represented by the peculiar CNS immunological milieu and the numerous systemic and local immunosuppressive forces exhibited by malignant gliomas to avoid immune recognition and cellular death. This review describes the current status of checkpoint modulation as treatment for malignant gliomas. We start illustrating the compelling molecular and immunological rationale, than we show striking preclinical evidence of activity and discuss available data from prospective clinical trials. Furthermore, we explore the role of predictive biomarkers of responsiveness to checkpoint blockade in the context of gliomas, along with the development of combinatorial and potentially synergistic approaches with other established anti-cancer treatments or complementary immunotherapeutic modalities.
Insights
Immune checkpoint inhibitors show promise for treating glioblastoma, a deadly brain cancer. Research explores their effectiveness, overcoming CNS immune barriers, and combining them with other therapies for better outcomes.
Area of Science:
- Neuro-oncology
- Immunotherapy
- Cancer Research
Background:
- Glioblastoma is an aggressive brain tumor with poor prognosis despite standard treatments.
- Novel therapeutic strategies are essential due to the limited efficacy of current therapies.
- The central nervous system (CNS) is recognized as immunoactive, challenging previous assumptions.
Purpose of the Study:
- To review the current status of immune checkpoint modulation for glioblastoma treatment.
- To explore the rationale, preclinical evidence, and clinical trial data for checkpoint inhibitors in gliomas.
- To discuss predictive biomarkers and combinatorial approaches for glioblastoma immunotherapy.
Main Methods:
- Review of molecular and immunological rationale for checkpoint inhibitors.
- Analysis of preclinical data demonstrating activity against gliomas.
- Discussion of data from prospective clinical trials involving checkpoint blockade.
Main Results:
- Immune checkpoint inhibitors have shown significant success in other cancers, prompting investigation in brain tumors.
- The CNS immunological environment and glioma-induced immunosuppression present challenges to effective antitumor immunity.
- Preclinical studies and early clinical data suggest potential activity of checkpoint modulation in malignant gliomas.
Conclusions:
- Checkpoint modulation is a promising area for glioblastoma treatment, despite CNS-specific challenges.
- Further research into predictive biomarkers and combination therapies is crucial for optimizing outcomes.
- Understanding the interplay between gliomas and the immune system is key to developing effective immunotherapies.